VISE Fall Seminar Series: Thursday, September 8
Title: Data-driven Healthcare: Perspectives from the Interface of Data Science, Research & Development, and Clinical Medicine
Speaker: Nicholas Marko, MD, Chief Data Officer & Director of Neurosurgical Oncology, Department of Neurosurgery, Geisinger Medical Center
Date: Thursday, September 8, 2016
Time: 12:10 start, noon lunch
Place: Stevenson Center 5326
Short Biography: Dr. Nicholas Mark, MD graduated from George Washington University in 2000 and from medical school in 2005. He also spent 2003-2004 as a Howard Hughes Institute Medical Student Fellow at The Institute for Genomic Research (TIGR) working with the computational biology and human gene expression groups to generate and analyze large genomic data sets. After completing neurosurgery residency at Cleveland Clinic in 2011, he was awarded the prestigious American Association of Neurological Surgeons William P. VanWagenen fellowship. This allowed him to conduct additional training and research using large-scale data sets at the interface of applied mathematics and translational oncology with the University of Cambridge Department of Applied Mathematics & Theoretical Physics and the Cancer Research UK Cambridge Cancer Institute. When he returned to the United States, he completed a neurosurgical oncology fellowship in 2013 at the MD Anderson Cancer Center in Houston, Texas and focused his research during this time on personalized predictive analytics for patients with brain cancer. Dr. Marko joined Geisinger Medical Center in Danville, Pennsylvania, in 2013 to direct the neurosurgical oncology program. In 2014, in addition to creating and leading the data science and engineering department and chairing the system’s enterprise data strategy committee, he was named Geisinger’s first Chief Data Officer (CDO). As CDO, Nick led four teams: Data Science, Data Governance, Data Management (enterprise data warehouse / big data / BI), and Enterprise Data Strategy. Throughout all of this Dr. Marko has also maintained his translational research efforts, studying molecular variability in glioblastoma. He has also continued to practice clinically as a neurosurgical oncologist, focusing on the surgical management of patients with malignant brain and spine tumors.